The following evidence profiles have been produced by applying the GRADE working group approach to determining the quality of evidence to the questions addressed. More information on this approach is contained in Section 2.
A1.1. Is methadone effective for the treatment of opioid dependence? (PDF, 62K)
A1.2. Does opioid agonist maintenance treatment reduce the spread of HIV? (PDF, 62K)
A1.3. Is buprenorphine effective for the treatment of opioid dependence? (PDF, 61K)
A1.4. Methadone versus buprenorphine (PDF, 70K)
A1.5. What maintenance doses of methadone should be used? (PDF, 70K)
A1.6. Tapered methadone versus alpha2 adrenergic agonists for withdrawal from opioids (PDF, 60K)
A1.7. Medications for opioid withdrawal (PDF, 63K)
A1.8. Should antagonists with minimal sedation be used for opioid withdrawal? (PDF, 61K)
A1.9. Should opioid antagonists with heavy sedation or anaesthesia be used for opioid withdrawal? (PDF, 63K)
A1.10. Should withdrawal from opioids be conducted in inpatient or outpatient settings? (PDF, 60K)
A1.11. Should antagonist pharmacotherapy, naltrexone, be used for the treatment of opioid dependence? (PDF, 61K)
A1.12. Should psychosocial treatments be used in addition to pharmacological maintenance treatments? (PDF, 61K)
A1.13. Is psychosocial assistance plus pharmacological assistance for opioid withdrawal more useful than pharmacological assistance alone? (PDF, 62K)
